2014

Chimerix Appoints Timothy W. Trost Senior Vice President, Chief Financial Officer

DURHAM, N.C., March 28, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, announced today that Timothy W. Trost has joined the company as Senior Vice President, Chief Financial Officer.

Mr. Trost brings to Chimerix more than 30 years of experience working in the financial field, combining strong executive management skills with an extensive financial background.  In this newly-created position, Mr. Trost will be responsible for overseeing the company's financial operations, reporting to Kenneth I. Moch, Chimerix's President and Chief Executive Officer.

"Tim is a seasoned industry executive whose depth and breadth of leadership experience significantly strengthen the Chimerix management team," said Mr. Moch. "Tim has been consulting for Chimerix since last fall and has been an important part of the team in securing both the recently announced Series F financing as well as the BARDA contract."

Prior to joining Chimerix, Mr. Trost was Vice President and CFO at Argos Therapeutics, Inc., a venture-backed immunotherapy company located in Research Triangle Park.  Previously, he was Senior Vice President and CFO at InteCardia, Inc., a venture-backed cardiac imaging company.  While at InteCardia, Mr. Trost played a key role in negotiating and executing the sale of the company to Syncor International Corporation. Prior to InteCardia, Mr. Trost served as Executive Vice President and CFO of Coastal Physician Group, Inc., a contract provider of emergency room physicians, having joined the company as Vice President of Corporate Development.  He also held the positions of Vice President of Finance at Morganite North America, Inc., and Senior Manager at Price Waterhouse.  Mr. Trost holds a B.S. in Accounting from the University of Illinois at Urbana-Champaign and is a Certified Public Accountant.

About Chimerix

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.

The company's lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA (dsDNA) viral diseases. Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug's antiviral activity in humans.

Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an open-label study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses. The open-label study builds on Chimerix's extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs. CMX001 has been well tolerated in all studies.

CMX001 is also being developed as a medical countermeasure in the event of a smallpox release. Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases.

Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies. Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses. A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.

Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs. For additional information on Chimerix, please visit http://www.chimerix.com.

SOURCE Chimerix, Inc.



RELATED LINKS
http://www.chimerix.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.